Skip to content
06 Oct 2019
A urinary tract infection (UTI) is a type of infection that can occur in the urinary tract, urethra, bladder and kidneys. People often confuse a UTI and cystitis – essentially, cystitis is a specific type of UTI that affects the bladder. To learn more about probiotics and cystitis, read the article Could probiotics help with cystitis?
We are seeing the incidence rates of UTIs increase annually. A global study in 2013 found over 92 million people suffered with UTIs worldwide1. Furthermore, the study found a 16% rise in UTI numbers from 1990 to 2013. In the UK, UTIs in the primary care system have increased 102% from 2001 to 20112, and in 2011, the Health Protection Agency estimated 14% of all antibiotics prescribed were for UTIs. This costs the NHS at least £124 million a year3, 4.
Anyone can suffer with a UTI, from babies to the elderly. The risk increases as you get older and women are at higher risk than men. Sometimes genetics also play a role in your susceptibility. It is estimated that 50-60% of women will develop at least one UTI in their lifetime5. It is less common for children and babies to get UTIs, but if you suspect your child might be suffering with one, they should always be seen by a GP.
Symptoms can include:
Symptoms can sometimes be embarrassing for the individual and affect their quality of life if the infection is recurring or not treated.
UTIs do not always clear on their own. The NHS states if symptoms have not cleared after a few days, it is worth visiting your GP as you will likely needs antibiotics.
The World Health Organisation states that UTIs may occur either because of the virulence of the pathogen causing the disease, the susceptibility of the host or a combination of both factors.
UTIs are caused by pathogenic (harmful) bacteria that enter the urinary tract area. They are most commonly caused by Escherichia coli but other pathogens may also cause infection. These include Proteus mirabilis, Staphylococcus saprophyticus, Enterococcus faecalis, Group B Streptococcus, Pseudomonas aeruginosa and Klebsiella spp.5, 6. The most commonly accepted theory is that pathogens are able to travel from the gut to the uro-genital tract. They translocate across the perineum, and ascend to the bladder via the urethra. Here they can cause cystitis.
E. coli and other pathogens are known causes of a UTI
Some pathogens are able to further migrate and travel to the kidneys via the ureters. This is why women are more at risks of UTIs, as their urethra is much shorter and closer to the anus. Interestingly, it has been shown in women who have recurrent UTIs, their daughters are at a higher risk of UTIs7.
To be successful, pathogens must display specific virulence factors in order to cause disease. They often require flagella (tail-like structures) to help them move from the genital region across to the urethra and bladder. Once there, they must be able to adhere well to the bladder lining, meaning they require specific attachment molecules (pili).
They must also be able to tolerate an immune response from the body, and one of the ways they can do this is through biofilm formation6. A biofilm is a protective layer (made from a mix of proteins and polysaccharides) that bacteria can produce around themselves. It makes an antibiotic’s (find out more about taking antibiotics with probiotics) job very difficult, as it is hard to penetrate and target the bacteria hidden inside. Once protected by the biofilm, pathogens can then produce toxins which can result in inflammation and tissue damage.
The ability to cause disease will depend on the virulence factors mentioned above, but some pathogens may be thwarted before causing disease if the environment they are entering – the urinary microbiome – is well-protected.
Scientists believed for many years that the urinary tract was sterile, until very recently. Thanks to advanced technologies in metagenomics, research has shown that certain microbes do exist in the urinary tract, albeit at low numbers. The most common genera present are Lactobacillus (the most dominant genus), Gardnerella, Cornyebacterium, Streptococcus, Actinomyces and Staphylococcus8-10. This differs to the microbiomes found in the gut, mouth and skin, and, like most of these human microbiomes, the urinary microbiome is unique to each individual.
Despite this, there are some similarities between the urinary and vaginal microbiome. Both regions are dominant in lactobacilli and some of the genera present are similar. However, it is not clear how these microbiomes interact with one another.
Generally, no definitive healthy urinary microbiome has been defined, however some suggestions have been posited. A study in 2013 looked at how the urinary microbiome can differ between individuals of different age and genders11. The researchers proposed that actually a ‘core’ microbiome can be observed, but may differ slightly depending on age. A core profile was seen across all women, but additional types of bacteria were seen within the different age groups (20-49, 50-69 and 70 years+), especially in the eldest age group.
Furthermore, the average total number of bacteria decreased as age increased, for both women and men. They also found that women have a different urinary microbiome to men, with women displaying a wider diversity of microbes. Similar results have also been shown in additional studies12-14. Although these results are interesting, it should be noted that the sample size used for this initial study was small, and more research is needed to ascertain differences in urinary microbiome composition.
As mentioned above, a number of different things can influence our urinary microbiomes. These include:
many factors, including dehydration, can contribute to the development of a UTI
There could also be many more. Research is still in its early days. It is likely that factors which affect vaginal health could also influence urinary health (hormones, perfumed products, tight clothing, douching etc.). This is supported by a study in 2009, in which the researchers showed that women with bacterial vaginosis (BV) had an increased risk of developing a UTI19. This could explain why menopausal women are at a higher risk of UTIs. As oestrogen levels drop, numbers of lactobacilli in the vaginal tract drop too, thus increasing the likelihood of BV.
It is not surprising that antibiotics impact the urinary microbiome, as antibiotics are damaging on commensal organisms in the gut and vaginal tract. They are not very selective, and as such often kill and inhibit bacteria they are not directly targeting. When this happens, it can lead to bacterial imbalances (dysbiosis). It also provides opportunities for potentially harmful bacteria to flourish and can make the individual vulnerable to infection.
The importance of the microbiome has been extensively studied in the gut and vagina, but less is known about the benefits of the urinary microbiome. As the urethra opens to the external outside environment, the urinary tract is potentially more exposed and vulnerable. The urinary microbiome may be able to offer protective benefits.
In the gut and vaginal tract, the microbiomes support the host in many ways, one of which is protecting against infection from pathogenic microbes. This is also thought to be the case in the urinary tract. Commensal organisms can adhere to and line the epithelial cells in the urinary tract. This forms a protective barrier, obstructing pathogenic organisms from binding, and reducing the risk of biofilm formation.
Commensals might also be able to compete with pathogens for nutrients as well as produce anti-microbial substances such as lactic acid and bacteriocins. This may reduce the overall risk of infection by pathogens.
In the gut, the microbiome and immune system are in constant communication. There are some immune cells located in the urinary tract, but there has been little research documenting this relationship.
Another thing to consider is that the urinary microbiome will come into contact with high levels of toxins. Toxins that have been removed from the bloodstream through kidney filtration get stored in the bladder. This interaction between the toxins and microbes may impact risks of diseases, though again, there is limited research investigating this14.
All of this considered, if probiotics can be used as an intervention in the gut and vaginal microbiomes, then could they be used in the urinary microbiome for UTIs, too?
Due to the potential protective role of the urinary microbiome against UTIs, there might be an opportunity to intervene with probiotics. Approximately 20-30% of women will suffer with recurring UTIs throughout their lives20. Antibiotic treatments are usually given, but antibiotic resistance is becoming an increasing problem globally, and other treatment options can be limited for some women. Probiotics could offer a solution in this case, to reduce the need for antibiotics and potentially enhance the action of any antibiotics used.
A large, double-blind, randomised trial published in 2008 showed a probiotic combination able to reduce the number of UTIs per year21. The one-year study included 252 postmenopausal women with a history of recurrent UTIs. The women were split into two groups, and were either given a probiotic combination of Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14® (Read all about these strains on the Probiotics Database: Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14®) or an antibiotic (trimethoprim-sulfamethoxazole) to take daily over the year. Results showed the number of UTIs had halved in both groups.
In the antibiotic group, UTIs had dropped from 7 to 2.9 UTIs per year, and in the probiotic group, UTIs had dropped from 6.8 to 3.3 UTIs per year. Additionally, antibiotic resistance had increased in the antibiotic group from starting values of 20-40% up to 80-95%. No resistance was observed in the probiotic group. These results could have been due to the fact that these probiotic strains were initially isolated in the urogenital tract.
As such, they exhibit high adherence capabilities and are able to support the probiotic barrier effect. They’ve also been shown to exhibit high anti-microbial activity against E. coli and produce the antimicrobials required to inhibit pathogens and breakdown pathogen biofilms.
Another trial looking at these specific strains (L. rhamnosus GR-1® and L. reuteri RC-14®) was conducted in premenopausal women22. This study found a reduction in recurring UTIs from 47% to 21% during a 6-month period. A similar study investigating L. rhamnosus GR-1® and L. reuteri B-54 were also able to significantly reduce the number of recurring UTIs in premenopausal women from 6 to 1.6 UTIs per year23.
A different double-blind study looked investigated 100 premenopausal women that had all suffered with at least 1 UTI in the last year24. The women were randomised and were given either a probiotic (Lactobacillus crispatus) or placebo following antibiotic treatment for a UTI. In the probiotic group, a recurrent UTI occurred in 15% of the women compared to 27% in the placebo group. Furthermore, the vaginal tract showed higher levels of colonisation with the probiotic.
A study in 2014 showed the urinary microbiome may also be linked to urge urinary incontinence (UUI)16. This study also found that a commensal organism, L. crispatus, is associated with a lack of symptoms for UUI. The exact mode of action is unknown, but it was suggested that this protective influence could come from the barrier effect of the species. There could also be a connection between the urinary microbiome and brain, like the gut-brain axis, this may also affect UUI. L. crispatus has also been shown to have high anti-microbial activity against E.coli and Candida albicans18.
The studies investigating probiotics and UTIs are mixed – some have shown very promising and exciting effects, whilst others have reported little. It is therefore essential to select probiotics that have been well-researched to reach the intimate area and have good adherence qualities. Choose strains that have research for intimate health, specifically UTIs, such as those detailed above.
There are a number of things that women in particular can do to look after your urinary health and limit the instances of UTIs, including:
Practising good health and hygiene are always a good way to maintain your wellbeing. If you are concerned about any symptoms you may be experiencing, it’s always a good idea to see a doctor.
For further reading, you may be interested in the following articles:
1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4.
2. Bardsley et al., (2013). Is secondary preventive care improving? Observational study of 10-year trends in emergency admissions for conditions amenable to ambulatory care. BMJ. 3(1). Online
3. Health Protection Agency. English National Point Prevalence Survey on Healthcare-associated Infections and Antimicrobial Use, 2011: Preliminary data. Published 2012. Accessed Jan 20, 2016.
4. Plowman R et al. (2001). An economic model to assess the cost and benefits of the routine use of silver alloy coated urinary catheters to reduce the risk of urinary tract infections in catheterized patients. Journal of Hosp Infection. 48: 33-42.
5. Al-Badr et al., (2013). Recurrent Urinary Tract Infections Management in women: A review. Sultan Qaboos Univ Med J. 13 (3): 359-367
6. Flores-Mireles et al., (2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 13(5): 269-284
7. Ragnarsdottir B et al., (2011). Genetics of innate immunity and UTI susceptibility. Nat. Rev. Urol. 8: 449-468
8. Bersanelli M et al., (2019). The Urinary Microbiome and anticancer immunotherapy: The potentially hidden role of unculturable microbes. Targeted Oncology. 14 (3): 247-252
9. Mueller ER et al., (2018). The Female Urinary Microbiota. Curr Opin Urol. 27 (3): 282-286
10. Hilt E,E et al., (2014). Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. Journal of Clinical Microbiology. 52 (3): 871-6
11. Lewis D., (2013). The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults. Cell. Infect. Microbio. 3: 41
12. Siddiqui H et al., (2011). Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. BMC Microbiol. 2 (11): 244
13. Dong Q et al., (2011). The microbial communities in male first catch urine are highly similar to those in paired urethral swab specimens. PLoS One. 6 (5): e19709
14. Whiteside S,A., (2015). The microbiome of the urinary tract- a role beyond infection. Nature Reviews Urology. 12 (2): 81-90
15. Goneau L. W., et al. (2014). Selective target inactivation rather than global metabolic dormancy causes antibiotic tolerance in uropathogens. Antimicrob. Agents Chemother. 58, 2089–2097
16. Pearce M, M., (2014). The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. MBio. 5 (4): e01283-14
17. Kim J & Park Y., (2018). Lactobacillus and Urine Microbiome in Association with Urinary Tract Infections and Bacterial Vaginosis. Urogenit Tract Infect. 13 (1): 7-13
18. Liu F et al., (2017). Alterations of urinary microbiota in type 2 diabetes mellitus with hypertension and/or hyperlipidemia. Front Physiol. 8:126.
19. Sumati AH & Saritha NK., (2009). Association of urinary tract infection in women with bacterial vaginosis. J Glob Infect Dis. 1: 151–152
20. Beerepoot M & Geerlings S., (2016). Non-Antibiotic Prophylaxis for Urinary Tract Infections. Pathogens. 5 (2): 36
21. Beerepoot et al., (2012). ‘Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women’. Arch. Intern. Med. 172 (9): 704-12.
22. Reid et al., (1992). Influence of three day antimicrobial therapy and lactobacillus vaginal supposirtoies on recurrence of urinary tract infections. Clin Ther. 14 (1): 128-131
23. Red et al., (1995). Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Microecol Ther. 23: 32-45
24. Stapleton E, A., (2011). Randomised, placebo- controlled phase 2 trial of a Lactobacillus crispatus probiotic given intragainally for prevention of recurrent urinary tract infection. Clin Infect Dis. 52 (10): 1212-7